FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.
titan pharmaceuticals
FDA Approves Fanapt for Schizophrenia Patients
Maryland-based Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Fanapt (otherwise known as iloperidone) for the acute treatment of adult patients with schizophrenia.